^
    Back
    Association details:
    Biomarker:CCL20 underexpression
    Cancer:Multiple Myeloma
    Drug:Empliciti (elotuzumab) (CS-1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Onco Targets Ther
    Title:

    Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide

    Published date:
    04/21/2021
    Excerpt:
    The expression of CCL20 was decreased in lenalidomide and Elotuzumab resistant U266 cells and in RRMM patients. CCL20 could therefore possibly increase the sensitivity of lenalidomide and Elotuzumab.
    DOI:
    10.2147/OTT.S300328